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Nicolas Novitzky,1,2 Valda Thomas,2 Cecile du Toit,1 Andrew McDonald1For patients with acute myelogenous leukemia (AML) who are unable to secure an acceptable HLA donor,
the role of autologous stem cell transplantation (auto-SCT) has remained controversial. Its effectiveness re-
mains unclear as, when analyzed on intention-to-treat strategies, a significant number do not undergo the
procedure, whereas others seem to fail therapy from pretransplant recurrences. To improve our counseling
to our patients on these 2 therapeutic options, we compared the outcome of patients in first remission of
AML who actually underwent autologous or allogeneic transplantation. The choice for the type of graft was
based on availability of HLA identical siblings. Patients received myeloablative conditioning followed by allo-
geneic or autologous cytokine mobilized peripheral blood stem cell transplantation. For prophylaxis of graft-
versus-host disease (GVHD), grafts were incubated ex vivo with anti-CD52 antibodies and patients were
prescribed cyclosporin until day 90. Patients were stratified by clinical and laboratory factors as well as cy-
togenetic risk. The endpoints were treatment-relatedmortality (TRM), disease-free survival (DFS), and over-
all survival (OS). The median presentation age for both transplant groups was 35 (14-60) years. Of the 112
consecutive patients achieving remission, autologous or allogeneic grafts were transplanted to 43 and 32 pa-
tients, respectively. There was no significant difference in the presentation clinical features, laboratory pa-
rameters, marrow morphology, or proportion of low and intermediate cytogenetic risk for both
transplant options. Treatment mortality as well as relapse rate was similar (14% and 15%; 39% and 27%, re-
spectively). At a median of 1609 and 1819 posttransplant days, 56% and 63% in each group survived. In uni-
variate analysis performance status, cytogenetic risk, morphologic features of dysplasia, blast count, and
lactate dehydrogenase (LDH) were significant factors for survival. Although for the entire group there
was no difference in survival between both modalities, all patients with unfavorable cytogenetics receiving
an autologous graft died of disease recurrence (3-year survival 35% versus 0%; P 5 .05). We conclude
that patients with AML who have low or intermediate cytogenetic risk undergoing myeloablative condition-
ing followed by autologous or allogeneic T cell–depleted stem cell transplantation appeared to have similar
outcome. However, those with unfavorable karyotype are unlikely to be cured with autologous grafts and are
candidates for experimental modalities.
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The overall outcome of patients with acute mye-
logenous leukemia (AML) seems to have improved
over the last 2 decades [1]. Some of the reasons for
this success include better disease stratification, supe-
rior supportive care, as well as greater access to trans-
plantation, particularly for older patients. However,
despite the fact that most individuals who are younger
than 60 years will achieve remission, the majority is
still likely to die of the malignancy [2-4]. Following
initial complete responses, postremission therapy may
include further standard-dose combination chemo-
therapy, various schedules of dose-intensified cytara-
bine (alone or combined with other agents [5-7], and875
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plantation (SCT) [8-12]. Although allo-SCT remains
an effective therapeutic option, particularly if patients
have unfavorable disease factors, high transplant-
related mortality remains a problem. Moreover, in
our community, many patients do not have HLA com-
patible donors, particularly if they are not of Caucasian
ancestry.
Auto-SCT was also shown to be an effective strat-
egy designed to enhance postremission dose intensity,
with acceptable procedure-related mortality and lead-
ing to long-term survival [8,9,11,13]. Although in
AML, most studies have confirmed superiority of
allo-SCT, the results were less certain for those who
did not have allogeneic donors and were randomized
to receive intensified doses of cytarabine (HDAra-C)
or auto-SCT [8,13]. The reason for this lack of
clarity is that early disease recurrence and ‘‘time
censoring’’ [14] becomes an important bias in the au-
tologous transplantation group by excluding those
who relapse early. Moreover, in the intention-to-
treat strategy, analysis of certain studies was further
complicated as up to 50% of patients randomized
into the autologous transplantation arm failed to
receive the allocated treatment [8]. Specifically,
intention-to-treat analysis may underestimate the
favorable outcome of those who actually go through
the procedure. When only patients who have indeed
undergone the procedure were compared to the
chemotherapy arms, in certain studies, the outcome
following autologous transplantation appeared supe-
rior and even comparable to the allogeneic group [8].
Considering these conflicting data and to better coun-
sel our patients who enquire about cost benefits of the
various treatment options, we decided to review our
experience by comparing the outcomes of consecutive
patients with AML who had been biologically strati-
fied according to the availability of an HLA identical
donor and who had actually received the allocated
transplantation strategy as the postremission therapy
for AML.DESIGN AND METHODS
Between January 1995 and January 2009, 2 consec-
utive prospective phase II trials were conducted in
patients with recently diagnosed AML. In these stud-
ies, 2 different doses of daunorubicin were used for
induction of remission and during consolidation ther-
apy. The first study, named Cape Town regimen 4
(CTR-IV), entered patients until October 1997,
whereas the subsequent trial (CTR-V) was activated
thereafter. In both cohorts, once postinduction ther-
apy had been completed, and based on the availability
of HLA identical donors, eligible patients were strati-
fied to receive allo- or auto-SCT. Consent for therapywas obtained according to the directives of the Univer-
sity of Cape Town.
Diagnosis of AML was according to the French,
American, British (FAB) classification [15], but
patients with promyelocytic leukemia (M3) were
excluded. At presentation morphologic assessment,
immunologic cell surface membrane marker analyses
and cytochemical stains were performed on the malig-
nant population following the recommendations of the
International Committee for the Standardization in
Hematology [16]. Whenever possible, cytogenetic
analysis of the presentation bone marrow blasts was
undertaken and karyotypes were classified according
to Cytogenetic Nomenclature (ISCN1995) criteria
[17]. Patients were then divided into 3 prognostic sub-
groups according to karyotype analysis. The following
criteria were used: patients with a favorable (t[8;21],
inv[16]) karyotype without additional unfavorable
cytogenetic abnormalities were only referred to SCT
if they had at least 1 unfavorable risk factor such as
hyperleucocytosis [18] or extramedullary masses [19].
Intermediate risk was considered for those with no
karyotypic abnormality, 18, 121, 122, del(9q),
11q23 rearrangement, and other numeric or structural
abnormalities. Twenty analyzed metaphases were re-
quired to include a patient in the cytogenetic normal
karyotype. Unfavorable risk was defined by the pres-
ence of monosomies or deletions of chromosomes
5 and 7 (25, 27, del 5q-, del 7q), abnormalities of
chromosome 3 (t[q21;q26], t[6;9][p23;q34], t[9;22]
[q34;q11]), or complex cytogenetic abnormalities (de-
fined as at least 4 unrelated cytogenetic clones) [20].Initial Chemotherapy and Supportive Measures
Patients entered into both induction programs re-
ceived similar supportive measures. On admission,
a double-lumen indwelling catheter was placed into
a deep thoracic vein of all eligible patients [21]. For
CTR-IV, patients were treated with continuous infu-
sion of cytarabine at 100 mg/m2 for 7 days, etoposide
100 mg/m2 daily for 7 days, and daunorubicin 45
mg/m2 on days 1, 2, and 3. Once the hematopoiesis
had recovered, patients achieving remission received
similar chemotherapy twice as consolidation therapy
and then, based on the availability of HLA identical
donors, they were stratified to receive auto- or allo-
SCT [22]. Patients treated with CTR-V were treated
with similar induction therapy, but daunorubicin was
escalated to 75 mg/m2 on each of the same 3 days. As
a difference to CTR-IV, in the follow-on cohort, be-
cause of the higher accumulative dose of anthracycline
in the induction sequence, only 1 consolidation sched-
ule was planned, and the dose of daunorubicin was re-
duced to 60 mg/m2 on each of the 3 consecutive days.
Patients failing to achieve remission with 2 courses of
induction therapy were considered as treatment
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duction and consolidation chemotherapy as well as
during the neutropenic period of transplantation, pa-
tients received oral antibiotic prophylaxis with ofloxa-
cin 200 mg twice daily, fluconazole 400 mg daily, or
amphotericin lozenges every 6 hours. When fever un-
related to transfusions or concurrent medication was
.38C, a fourth-generation cephalosporin in combi-
nation with an aminoglycoside or a glycopeptide was
immediately commenced and modified according to
the results of blood and other cultures. Individuals
were transfused with filtered and irradiated blood
products to maintain the hemoglobin level above 7
g/dL and the platelet count between 10 and 20 
109/L. Hematopoietic growth factors were not rou-
tinely used. To confirm clearance of leukemia,
a bone marrow biopsy was performed on day 14 of in-
duction chemotherapy, and unresponsive patients
(.50% blasts) were withdrawn from study. If remain-
ing blasts were between 5% and 50%, patients received
a similar 3-drug reinduction. Following chemother-
apy, remission status was confirmed by morphology
and standard karyotyping on days 28 to 35. For all pa-
tients, the Cancer and Leukemia Group B (CALGB)
criteria for response to treatment and relapse were
used [23]. Complete remission required normal
peripheral blood and leukocyte (ie, platelets .100 
109/L, polymorphonuclear leukocyte [PMN] .1.5 
109/L, hemoglobin.12 g/dL) with adequate differen-
tial counts as well as morphologically normal marrow
containing\5% blasts. Among patients who achieved
complete remission (CR), relapse was defined as the
presence of.10% blasts in the bone marrow or blasts
in extramedullary sites.Preparation for Transplantation
Eligibility criteria for transplantation in the 2 types
of transplants were similar for both trials and included
patients of age 13 to 60 years with newly diagnosed
AML achieving CR and receiving consolidation
therapy as per individual protocol, adequate perfor-
mance status (0, 1, or 2 on ECOG scale), and nonreac-
tivity on testing for the human immunodeficiency
virus. All consenting individuals were eligible for mye-
loablative therapy and, based on the availability of
HLA-identical siblings, received T cell–depleted allo-
geneic (CAMPATH-1H/alemtuzumab [24,25]) or
autologous cytokine-mobilized blood stem cell trans-
plants. Whenever possible, patients were nursed in
laminar down-flow isolation rooms. Patients with
AML progressing from myelodysplasia/myeloprolif-
erative syndromes and those with leukemia secondary
to previous exposure to radiation or cytotoxic agents
were excluded. Other disqualifying criteria were heart
ejection fraction of \45%, symptomatic ischemic
heart disease, or recent myocardial infarction. Thefocus of the current investigation was to determine
the difference in outcome of patients pooled from
both trial groups and who had completed postremis-
sion therapy with auto- or allo-SCT.
Myeloablative Conditioning
Two myeloablative conditioning protocols were
used during the trial. One was radiotherapy based,
whereas the other included cytotoxic agents only.
The allocation of the type of conditioning was derived
from the availability of radiotherapy space in a busy
tertiary hospital oncology program. The radiation-
based conditioning regimen was with fractionated
total-body irradiation (TBI) delivered in 6 twice-
daily fractions of 2 Gy (total 1200 cGy) and cyclophos-
phamide 60 mg/kg (with mesna cover) on days22 and
21 [23,25]. When radiotherapy was not available,
individuals received conditioning with oral busulfan
1 mg/kg, 6 hourly  12, melphalan 70 mg/m2 on 2
consecutive days (total dose 140 mg/m2), followed by
cyclophosphamide 120 mg/kg daily in 2 divided
doses. In the allogeneic group posttransplantation,
patients received prophylaxis with valacyclovir 1 g
every 8 hours, and after engraftment, cotrimoxazole
180 mg for 3 months.
Collection of Stem Cells for Transplantation
For the mobilization of hematopoietic progeni-
tors, HLA identical sibling donors were treated with
granulocyte-colony stimulating factor (G-CSF) 5-10
mg/kg/day injected subcutaneously on 5 consecutive
days. Large-volume apheresis was started approxi-
mately 4 hours after the last dose of G-CSF. The num-
ber of CD341 cells was determined according to the
guidelines of the International Society for Hemato-
therapy and Graft Engineering [26]. Based on the
patient’s actual body weight, the target cell dose was
2  106 CD341 cells/kg. In the event that the target
cell dose was not achieved, apheresis was repeated
the following day. For graft-versus-host disease
(GVHD) prophylaxis, stem cell–rich products were
treated with CAMPATH-1H (until 2004, kindly pro-
vided by G. Hale; Antibody Therapeutic Centre,
Oxford, UK) or alemtuzumab at a dose of 1-2 mg/1010
MNC cells that was added ‘‘into the bag,’’ allowed to
react at 20C for 30minutes, and infused intravenously
without washing [27]. Intravenous cyclosporin was
commenced on day –1 at a dose of 3 mg/kg in 2 divided
doses, maintaining always a therapeutic serum level.
Upon recovery of the gastrointestinal tract from the
effects of the conditioning, cyclosporin was continued
as an oral formulation until day 90 [24,27]. GVHDwas
defined according to the Seattle criteria [28]. Acute
GVHD (grades II-IV) was treated with systemic pred-
nisone (2-10 mg/kg/day) with or without cyclosporin
(with close monitoring of blood levels). Once this
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tapered off according to clinical response.
For patients undergoing auto-SCT, the peripheral
blood progenitor cell (PBPC) mobilization protocol
included etoposide 2 g/m2, followed by G-CSF at 5
mg/kg twice daily, commencing on day 5 and contin-
ued until stem cell collection was completed. When-
ever possible, a large-volume (.4 blood volumes)
apheresis strategy was instituted so that a minimum
of 5-10  108/kg mononuclear cells and .2  106/
kg CD341 cells could be harvested with 1 procedure.
PBPCs were collected and transferred into cryopreser-
vation bags (Charter Medical, Winston-Salem, NC;
catalog number 72.005) containing, respectively,
10% of AB serum and DMSO. Stem cell–rich concen-
trates were cryopreserved employing a controlled rate
programmable freezer at 21C/min to 280C and
stored in liquid nitrogen tanks (Linde/AGA, Oslo,
Norway) until transplantation. At least 36 hours after
the last dose of conditioning chemotherapy (day 0), au-
tologous grafts were thawed at the bedside in a 37C
sterile water bath and infused intravenously without
the addition of any filters.Statistical Analysis
The chi-square statistic or Fisher’s exact tests were
used to establish differences in the distribution of
discontinuous variables and Student’s t-test or the
Mann-Whitney-Wilcoxon rank sum test to compare
continuous variables. All reported P values are 2-sided.
The disease-free survival (DFS) was calculated from
the date of transplant until the date of first relapse or
of death in first CR. Overall survival (OS) was calcu-
lated from transplant until death from any cause, and
surviving patients were censored at last follow-up. Sur-
vival estimates were obtained by the method of Kaplan
and Meier, and statistical significance in the difference
was calculated using the log-rank test. By definition, all
patients who died in CRwere considered as death from
treatment-related mortality (TRM). The probability
of TRM was estimated using cumulative incidence es-
timates. For the endpoint of TRM, disease progression
was regarded as a competing risk [14]. Patients who
died without disease progression were categorized as
TRM, whereas patients alive without progression
were censored at last follow-up, and those who suf-
fered disease progression were censored at relapse.
The cumulative incidence and time to onset of acute
GVHD (aGVHD) and chronic GVHD (cGVHD) re-
quired that patients survived for at least 15 and 100
days after transplant, respectively. Multifactorial non-
linear regression was used to analyze the possible rela-
tionship between survival and the following covariates:
type of graft, cytogenetic group, clinical and labora-
tory parameters, patient gender, patient age, donor
sex, antibody dose, and stem cell dose. The Cox modelwas also used to determine the independent prognostic
factors among those that appeared important in uni-
variate analyses (P\ .10). All data analyses were per-
formed using the Statistica (StatSoft Inc., Tulsa, OK,
USA) computer software package.RESULTS
Between 1995 and 2009, 158 patients with AML
were prospectively entered into 2 consecutive studies
testing the effectiveness of a 3-drug combination to
achieve remission and in the OS. CTR-V tested the
outcome of individuals who received for induction
therapy a higher dose of anthracycline. Table 1 shows
that there was no significant difference in the clinical
and laboratory parameters (including proportion of
patients with unfavorable cytogenetics) between the
2 treatment groups. Table 2 depicts the treatment out-
comes of patients entered into each of the 2 chemo-
therapy treatment groups. Analysis of the data
showed that higher-dose anthracycline induction ther-
apy was associated with superior remission rates,
higher CR with a single course of chemotherapy, and
higher OS, without significant increase in toxicity
(Table 2 [22]). Of the 158 individuals studied 71%
achieved CR, but 35% failed to complete the designed
treatment strategy and did not undergo transplanta-
tion. Table 2 shows the reasons for not proceeding
to transplantation for each treatment group.
Outcome of Transplantation Groups (Tables 3
and 4)
Evaluation for availability of HLA-compatible sib-
lings was performed in all patients with no exclusion
criteria for transplantation. In addition, those who
had become platelet transfusion refractory because of
lymphocytotoxic antibodies were also tested to deter-
mine possibility of family platelet donations. Of 90
patients tested, 37 had HLA identical donors, but 32
underwent allogeneic transplantation because in the
interim, 3 relapsed, and in 2 cases (favorable cytoge-
netics; CTR-V) the donors became unavailable, so
they also received autologous grafts. Thus, from the
original 158 individuals with AML, 29 in the CTR-
IV (10 allo and 19 auto) and 46 in CTR-V (24 auto
and 22 allo) groups received myeloablative condition-
ing and underwent SCT (Tables 1 and 2).
Conditioning was radiotherapy based in 12 patients
in the allogeneic transplant group and 14 in the
autologous transplant group. There was no
significant difference in the outcome according to
conditioning type. Table 3 shows that there were no
substantial pretransplant clinical or laboratory differ-
ences in the 2 transplant cohorts. Thus, although
there was significantly better response for the CTR-V
induction protocol, which resulted in better OS
Table 1. Clinical and Laboratory Data of Patients Entered into CTR-IV and CTR-V Protocols
All Patients
n 5 158
CTR-IV
n 5 71
CTR-V
n 5 87 P
Age, median (range) 35 (13-61) 34 (15-61) 35 (13-58) NS
Sex (F/M) 78/80 39/32 39/48 NS
Hb g/dL, median (range) 8.2 (2.1-15) 9 (2.1-15.0) 7.2 (2.6-13.3) .07
WCC  109/L, median (range) 16.15 (0.6-414.5) 13.75 (0.6-235) 16.8 (0.7-414.0) NS
Blasts  109/L, median (range) 7.27 (0-187) 3.55 (0-99) 8.9 (0-187) NS
Platelets  109/L, median (range) 47.5 (0-2732) 48.5 (0-608) 45 (6-2732) NS
LDH i.u., median (range) 671 (130-4185) 533 (130-4185) 744.5 (240-3895) .07
Cytogenetics n 5 86 n 5 35 n 5 51 NS
 Favorable 23% 24% 22%
 Intermediate 52% 55% 49%
 Unfavorable 27% 21% 29%
Performance status, median (range) 2 (1-4) 2 (1-4) 2 (1-4) NS
F indicates female; M, male; LDH, lactate dehydrogenase; WCC, white cell count.
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their long-term outcome was now not significantly dif-
ferent (Figure 1). Table 4 summarizes the outcome
data in the 2 transplant groups. The outcome
according to type of transplant was similar in the
favourable and intermediate cytogenetic risk; patients
with poor karyotype had significantly lower survival
(Figures 3 and 4). Transplant-related mortality was
not significantly different between the allogeneic or
autologous stem cell source groups and was mainly
related to infections. The leukemia recurrence rate
was also not significantly different, and 56% and
63% of the autologous and allogeneic cohorts survived
at a posttransplant median of 1609 and 1819 days, re-
spectively (Figures 2, 5, and 6).
Statistical Analysis
In the univariate analysis, the adverse factors for sur-
vival in the autologous transplantation group weremor-
phologic features of dysplasia, unfavorable cytogenetics,
performance status at presentation, remission requiring
.1 induction course, as well as lactate dehydrogenase
(LDH) and percent blasts at diagnosis. In the allogeneic
donor group, the corresponding factors included
morphologic dysplasia, unfavorable cytogenetics, per-
formance status, and requiring .1 treatment cycle to
achieve remission. Although the rate of leukemia
relapse, the proportion of surviving patients, as well as
the median OS favored allo-SCT, in this analysis, there
was no statistical difference with regard to TRM and of
the rate of relapses between the 2 myeloablative
conditioning groups (Table 4 and Figures 2, 5, and 6).
Cox regression analysis showed that in the autolo-
gous transplant set, presentation with elevated LDH
had worse outcome, whereas for both groups unfavor-
able cytogenetics were a significant adverse factor for
survival. Although cytogenetics was predictive of over-
all outcome for all patients, Figures 3 and 4 show that
patients with unfavorable cytogenetics did particularly
poorly in the auto-SCT group as all patients surviving
the procedure died of disease recurrence. To the con-trary, patients with favorable and intermediate risk
cytogenetics did equally well with auto or allo trans-
plantation, suggesting that allo transplantation has
a particularly important role for patients with unfavor-
able cytogenetics.DISCUSSION
There is consensus that following remission of
AML, allo-SCT offers superior protection from re-
lapse than various forms of chemotherapy [8,9,29].
However, several prospective trials compared the
survival after auto-SCT to postremission chemother-
apy, or no further therapy, but results have been con-
flicting [4,30]. The HOVON Group concluded that
after auto-SCT because of transplant-related mortal-
ity and lower subsequent remissions following re-
lapses, the no-therapy cohort had a nonsignificant
advantage in survival, but in this study, 214 of 344
(62%) were not randomized because of multiple rea-
sons [4]. In the smaller Hellenic study, although allo
SCT was found to be superior in both progression-
free survival (PFS) and OS, no difference in outcome
was observed between high-dose cytarabine and
auto-SCT. Patients with unfavorable cytogenetics
did particularly poorly [30]. However, although differ-
ences in outcome were not detected, patient numbers
in both arms were very limited. On the other hand,
in 3 large cooperative studies (European Organization
for Research and Treatment of Cancer/Gruppo
Italiano Malattie Ematologiche Maligne dell’Adulto
and MRC10), DFS was significantly longer in patients
treated with auto-SCT compared with chemotherapy
(48% versus 30% at 4 years and 53% versus 40% at
7 years, respectively) [13,29,31]. It also remains
unclear which is the most effective consolidative drug
schedule and the optimal number of cycles (1-4) of
HDAra-C as extended stay in the hospital is likely to
compromise compliance with therapy [1,8,32,33].
The influence of the presentation cytogenetic
pattern seems to be an important consideration on
Table 2. The Outcome of Patients Receiving CTR-IV and CTR-V Treatment Schedules Are Shown
Initial Therapy CTR-IV n 5 71 CTR-V n 5 87
Complete remission 44 (62%) 68 (78%; P 5 .02)
 CR first course 33 (46%) 58 (67%)
Reasons for failing to receive SCT n 5 15 (34%) n 5 24 (35%)
 2 refused further Tx  5 refused further Tx
 2 cardiac dysfunction  2 cardiac dysfunction
 2 platelet refractoriness  7 persistent infection
 3 persistent infection  7 relapsed
 5 relapsed  2 failed SCT collection
 1 unknown  1 platelet refractory
Underwent SCT 29 46
 Allogeneic 10 22
 Autologous 19 24
SCT indicates stem cell transplantation; Tx, treatment; CR, complete remission.
Patients in CTR-V achieved significantly higher CR rates.
880 Biol Blood Marrow Transplant 17:875-884, 2011N. Novitzky et al.long-term results. In the favorable cytogenetic risk
group, the treatment of core binding factor leukemia
(CBF) has been the subject of substantial debate. These
patients have good outcome, particularly if they
received postremission dose-intense cytarabine
(.3 g/m2); however, these patients also represent a
very heterogenous group [34,35]. Better survival with
auto-SCT was described, particularly if poor prognos-
tic factors such as hyperleukocytosis were present
[5,8,13], as the relapse rate after HDAra-C appeared
higher than previously reported [8,11,12,35]. Similar
observation was made in a multicenter intergroup
American study comparing younger patients who
received intensification with allogeneic (patients who
had HLA donor) versus autologous transplantation or
high-dose intensification chemotherapy (no donor
group). On an intention to treat, the OS were 98.1%
and 73.9% (NS), respectively [36]. Interestingly, those
with a low-risk karyotype benefited more from autolo-
gous transplantation than the allogeneic procedure, and
both forms of transplantation were better than
intensified chemotherapy [36,37]. In an EBMT
retrospective analysis of 166 patients with t(8;21),Table 3. Clinical and Laboratory Data of the 2 Stem Cell Transpla
All: 75/111
Age, median (range)
Females/males
Performance status, median (range)
CTR-IV/CTR-V
Days from consolidation to transplantation, median (range)
Hb g/dL, median (range)
WCC  109/L, median (range)
Blasts  109/L, median (range)
Platelets  109/L, median (range)
LDH i.u., median (range)
Cytogenetic risk
 Low
 Intermediate
 High
LDH indicates lactate dehydrogenase; WCC, white cell count; SCT, stem cellprevious treatment with high-dose cytarabine had
no protective effect [37]. Furthermore, patients with
normal karyotype remain a heterogenous group that
currently is being studied with molecular techniques.
These include patients with NPM1, FLT-3, CEBPA
mutations, and submicroscopic duplications of the
MLL gene [34]. Some of these patients are considered
to have more adverse prognosis and allo-SCT has also
been advocated for this cohort [1,38,39]. The
intergroup study as well as a recent meta-analysis
showed that allogeneic transplantation was superior to
the ‘‘no-donor group’’ [36,39]. However, in our
current investigation, most of these patients were not
tested with molecular techniques, so they were not
used in the decision-making process. Finally, for poor
cytogenetic risk patients, outcome was particularly
poor, and here, allogeneic transplantation was de-
scribed to be superior to the other forms of treatment
[36,39].
The topic remains inconclusive from other per-
spectives as well, as in the intention-to-treat stratifica-
tion strategy, a large number of patients failed to
complete the allocated treatment, leading in soment Treatment Groups
Auto SCT n 5 43 Allo SCT n 5 32
34 (14-65) 36 (15-58)
18/25 12/20
2 (1-3) 2 (1-2)
19/24 10/22 (P 5 .18)
69 (41-402) 88 (53-238)
8.2 (2.8-15) 8.05 (5.9-15)
16.15 (0.72-153) 15.4 (0.72-415)
13 (0-90) 4.45 (0-80)
45.5 (6-608) 42 (17-2732)
670 (187-1656) 587 (130-4185)
12 (28%) 8 (25%)
24 (56%) 14 (43%)
7 (16%) 10 (31%); P 5 .01
transplanatation.
Table 4. Summary of the Outcome Results of the 2 Transplant Groups
Outcome of SCT Auto SCT n 5 43 Allo SCT n 5 32
Nonrelapse mortality 6 (14%) 5 (15%)
 VOD 1 1
 Secondary malignancy 1
 Infections 4 3
 GVHD >1 — 1
Relapses 13 (39%) 7 (27%)
Alive (%) 24 (56%) 20 (63%)
Follow up, median days (range) 2177 (49-6058) 1441 (83-5851).
OS, median days (range) 1609 (149-5558) 1819 (83-5704)
Statistics:
Univariate analysis (P < .05)  Dysplasia  Dysplasia
 Cytogenetics  Cytogenetics
 PS  PS
 More than 1 induction course  More than 1 induction course
 Blasts
 LDH
Cox regression analysis  Cytogenetics (P 5 .012)  Cytogenetics (P 5 .012)
 LDH (P 5 .0019)
LDH indicates lactate dehydrogenase; SCT, stem cell transplantation; OS, overall survival; GVHD, graft-versus-host disease; VOD, veno-occlusion dis-
ease; PS: performance status.
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environment, because of the poor representation of
patients of Southern African and Mixed Race
ancestry in the local and international stem cell
donor registries (South African Bone Marrow
Registry, WBMD), in practice, only those who had
tissue identical siblings were able to receive an
allograft. On the other hand, auto-SCT would seem
to be an attractive approach in the management of pa-
tients as it requires a single admission, and patients in
remission are their own source of the graft, but because
of the heterogeneity of risk factors, its place still
requires elucidation [33-38]. Consequently, to give
greater insight of our local experience when
counseling our patients on these options, we
reviewed the outcome of patients with AML treated
in 2 consecutive protocols and receiving auto or allo
transplantation as the postremission strategy [22].
From the original 158 patients, 112 achieved remission
(44 and 68 patients, respectively), but Table 2 shows
that 34% and 35% did not receive the intended treat-
ment because of a number of reasons, including cardi-
otoxicity of induction chemotherapy, platelet
transfusion refractoriness because of broad-spectrum
HLA antibodies (and no available platelet donors),
persisting invasive infection, patient refusal, disease
recurrence, etc. Table 2 shows that although patients
receiving CTR-V program had significantly higher re-
sponses that led to longer OS, this seemed mainly the
result of higher proportion of patients achieving re-
mission and becoming available for myeloablative
postinduction therapy. Similar experience has been re-
cently published in a controlled trial, suggesting that
intensification of induction with higher-dose anthra-
cycles should be considered if there are no contraindi-
cations [40]. Thus, this analysis was conducted on onlythe 32 individuals undergoing allogeneic and 43 re-
ceiving autologous stem cell grafts. When patients in
remission were pooled as a single group (Figure 1)
and analyzed by type of transplant, there was no differ-
ence in survival between those who initially received
CTR-IV or CTR-V (Figure 2).
As shown in Table 3, patient presentation of clin-
ical and laboratory characteristics was not significantly
different between the 2 transplant options. A summary
of their outcomes shown in Table 4 (and Figure 2) re-
veals a superior survival for the allogeneic group, but
the difference was not significant, although the rela-
tively small patient numbers make further interpreta-
tion of these results difficult. Of note is that although
the allograft cohort had significantly higher propor-
tion of poor-risk karyotype AML patients than the
autograft group, OS appeared better. TRM was ac-
ceptable (15%), and despite T cell depletion of grafts
with Campath 1H/alemtuzumab, the relapse rate ap-
peared low at 27% (Figure 6). In the univariate analysis
for the autologous group, adverse factors influencing
survival included presentation of morphologic dyspla-
sia, unfavorable cytogenetics, performance status, .1
induction course, circulating blast number, and ele-
vated serum LDH. The first 4 factors were also rele-
vant in the allogeneic cohort. Cox regression analysis
confirmed that poor cytogenetics and high-serum
LDH in the autologous and adverse karyotype for
the allogeneic group resulted in worse outcome. Mor-
phologic dysplasia and elevated LDH have been re-
ported to exert prognostic value in myelodysplastic
syndrome (MDS) and AML, leading to unfavorable
outcome in a German study and may represent
a more aggressive population [41,42]. These results
may also suggest that some patients with secondary
leukemia could have been included, which are known
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Figure 1. Allo-SCT. Outcome according to trial.
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Figure 3. Allogeneic transplantation. Survival according to cytogenetic
risk.
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auto-SCT group, all patients with adverse cytogenet-
ics relapsed (Figure 4).
Two further issues seem relevant. First, patients
receiving allogeneic stem cells grafts had ex vivo im-
mune depletion of the graft with Campath-1H/
alemtuzumab as a form of GVHD prophylaxis. This
strategy has been associated with improvement of
the TRM, but has been linked with increased leukemia
recurrence by some, but not other investigators [43].
Although it is difficult to compare the conclusions of
retrospective studies because of variable patient selec-
tion, our results appear in line with other publications,
suggesting that prevention of early mortality from
complications of transplantation may have greater
overall impact on survival than that of recurrence of
leukemia, probably because NK cells seem to recover
rapidly after transplantation, and they have a critical
role in decreasing recurrence of leukemia. We haveSurvival According to Transplant Type
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Figure 2. Survival according to transplant type.previously described swift reconstitution of this popu-
lation by day 30 postgraft infusion in a similarly
treated cohort, perhaps explaining these favorable re-
sults [44]. Last, the preferred source of autologous
stem cells for transplantation has been debated over
the last decade, with suggestions that early recovery
with PBPC lead to lower TRM and better outcome
[45]. Although this may be correct, emerging evidence
that mobilized autologous blood cell transplants have
higher relapse rate than when bone marrow is trans-
planted, particularly if a higher CD341 population
is infused, may require a review of this strategy
[46,47].
We can thus summarize this investigation with the
following conclusions: (1) we verify previousAutologous Stem Cell Transplantation
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Figure 4. Auto-SCT. Survival according to cytogenetic risk.
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Figure 5. Allo-SCT. Cummulative proportion: cause of death.
Biol Blood Marrow Transplant 17:875-884, 2011 883Autologous Stem Cell Transplantation for AMLobservations that despite a proactive approach toward
transplantation, one-third of patients in CR1 did not
received the intended intensification strategy; (2) the
cytogenetic profile at diagnosis is confirmed as a criti-
cal prognostic factor; (3) in patients with de novo
AML who have low and intermediate cytogenetic
risk factors, auto-SCT is an effective consolidation
therapy, and in this category of patients both auto-
and allo-SCT appear to have similar outcome. Thus,
in our setting, considering the low representation of
the indigenous African racial populations we serve in
national and international stem cell registries and
the high treatment costs involved, auto-SCT appears
an effective strategy for patients with favorable and
intermediate-risk cytogenetics. (4) To the contrary,
auto-SCT has little protective role in patients with
AML and adverse karyotype, so rapid matched unre-
lated donor (MUD) search is mandatory, or alterna-
tive investigative strategies must be made available
for this group.Autologous Stem Cell Transplantation
Cumulative Proportion: Cause of Death
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Figure 6. Auto-SCT. Cumulative proportion: cause of death.ACKNOWLEDGMENTS
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